Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Sheima Farag"'
Autor:
Yvonne Schrage, Astrid W. Oosten, Alessandro Gronchi, Sheima Farag, Peter Hohenberger, Neeltje Steeghs, Hans Gelderblom, Mahmoud Mohammadi, Ingrid M.E. Desar, An K.L. Reyners, Patrick Schöffski, Piotr Rutkowski, J.W. van Sandick, Nikolaos Vassos, Esther Bastiaannet, Nikki S. IJzerman, Robin L. Jones, Marco Baia, Javier Martin-Broto
Publikováno v:
European Journal of Surgical Oncology, 47(8), 2173-2181. W.B. Saunders
European Journal of Surgical Oncology, 47, 8, pp. 2173-2181
European Journal of Surgical Oncology, 47, 2173-2181
EJSO-European Journal of Surgical Oncology, 47(8), 2173-2181. ELSEVIER SCI LTD
European Journal of Surgical Oncology, 47(8), 2173-2181. ELSEVIER SCI LTD
European Journal of Surgical Oncology, 47, 8, pp. 2173-2181
European Journal of Surgical Oncology, 47, 2173-2181
EJSO-European Journal of Surgical Oncology, 47(8), 2173-2181. ELSEVIER SCI LTD
European Journal of Surgical Oncology, 47(8), 2173-2181. ELSEVIER SCI LTD
Contains fulltext : 235268.pdf (Publisher’s version ) (Open Access) BACKGROUND: Oesophageal gastrointestinal stromal tumours (GISTs) account for ≤1% of all GISTs. Consequently, evidence to guide clinical decision-making is limited. METHODS: Clini
Autor:
Neeltje Steeghs, Hans Gelderblom, W.T.A. van der Graaf, Pieter A. Boonstra, Sheima Farag, Johannes J. Bonenkamp, F. van Coevorden, Ingrid M.E. Desar, Anna K.L. Reyners, B. van Etten, Dirk J. Grünhagen
Publikováno v:
EJSO, 45(3), 410-415. ELSEVIER SCI LTD
European Journal of Surgical Oncology, 45, 410-415
European Journal of Surgical Oncology, 45(3), 410-415. W.B. Saunders
European Journal of Surgical Oncology, 45, 3, pp. 410-415
EJSO-European Journal of Surgical Oncology, 45(3), 410-415. ELSEVIER SCI LTD
European Journal of Surgical Oncology, 45, 410-415
European Journal of Surgical Oncology, 45(3), 410-415. W.B. Saunders
European Journal of Surgical Oncology, 45, 3, pp. 410-415
EJSO-European Journal of Surgical Oncology, 45(3), 410-415. ELSEVIER SCI LTD
Background: A cohort of 201 patients with small bowel gastrointestinal stromal tumors (GIST) treated between January 1st, 2009 and December 31st, 2016 in five GIST expertise centers in the Netherlands was analyzed. Goal of this study was to describe
Autor:
Sheima Farag, Neeltje Steeghs, Nikki S. IJzerman, Lioe-Fee de Geus-Oei, An K.L. Reyners, Anne I.J. Arens, Ingrid M.E. Desar, Hans Gelderblom, Dirk J. Grünhagen, Matthijs P.M. Houdijk
Publikováno v:
Nuklearmedizin. Nuclear Medicine, 60, 06, pp. 411-416
Nuklearmedizin-Nuclear medicine, 60(6), 411-416. GEORG THIEME VERLAG KG
Nuclear Medicine-Nuklearmedizin, 60(6), 411-416. Georg Thieme Verlag
Nuklearmedizin, 60(06), 411-416. Schattauer GmbH
Nuclear Medicine, 60(06), 411-416. GEORG THIEME VERLAG KG
Nuklearmedizin. Nuclear Medicine, 60, 411-416
Nuklearmedizin-Nuclear medicine, 60(6), 411-416. GEORG THIEME VERLAG KG
Nuclear Medicine-Nuklearmedizin, 60(6), 411-416. Georg Thieme Verlag
Nuklearmedizin, 60(06), 411-416. Schattauer GmbH
Nuclear Medicine, 60(06), 411-416. GEORG THIEME VERLAG KG
Nuklearmedizin. Nuclear Medicine, 60, 411-416
Aim The aim of this study was to investigate the impact of 18F-FDG-PET/CT on treatment decision making in metastatic gastrointestinal stromal tumor (GIST) patients. Methods This study retrospectively evaluated 18F-FDG-PET/CT scans to monitor response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e05f6f857a4de8f8baea46e380e3926
https://repository.ubn.ru.nl/handle/2066/241384
https://repository.ubn.ru.nl/handle/2066/241384
Autor:
H. van Boven, J. W. Wilmink, Sheima Farag, A.C.J. van Akkooi, Neeltje Steeghs, Geerard L. Beets, L. E. van der Kolk
Publikováno v:
Familial cancer, 17(2). Springer Netherlands
Familial Cancer, 17(2), 247-253. Springer Netherlands
Familial Cancer, 17(2), 247-253. Springer Netherlands
Gastrointestinal stromal tumors (GISTs) occur mostly sporadically. GISTs associated with a familial syndrome are very rare and are mostly wild type for KIT and platelet-derived growth factor alpha (PDGFRA). To date 35 kindreds and 8 individuals have
Autor:
Neeltje Steeghs, Anna K.L. Reyners, Hans Gelderblom, Petra M. Nederlof, Winette T. A. van der Graaf, Neeta Somaiah, Pieter A. Boonstra, Robert S. Benjamin, Sheima Farag, Wei Lien Wang, Birthe Heeres, Dirk J. Grünhagen, Hester van Boven, Haesun Choi
Publikováno v:
European Journal of Cancer, 76, pp. 76-83
European Journal of Cancer, 76, 76-83
European Journal of Cancer, 76, 76-83. Elsevier Ltd.
European Journal of Cancer, 76, 76-83. ELSEVIER SCI LTD
European Journal of Cancer, 76, 76-83
European Journal of Cancer, 76, 76-83. Elsevier Ltd.
European Journal of Cancer, 76, 76-83. ELSEVIER SCI LTD
Purpose: Patients, platelet-derived growth factor receptor alpha (PDGFRA) D842V-mutated gastrointestinal stromal tumours (GISTs) are known for their insensitivity to imatinib. However, in clinical practice responses have been observed in some patient
Autor:
Stefan Sleijfer, Hans Gelderblom, Neeltje Steeghs, Arjan J. Verschoor, Jacob W. Bosma, Sheima Farag, J. Martijn Kerst
Publikováno v:
Journal of Clinical Pharmacology, 55(8), 920-925
Journal of Clinical Pharmacology, 55(8), 920-925. Wiley-Blackwell
Journal of Clinical Pharmacology, 55(8), 920-925. Wiley-Blackwell
Agranulocytosis is a rare but serious side effect of imatinib in gastrointestinal stromal tumor (GIST) patients. Imatinib is an inhibitor of the proto-oncogene tyrosine kinase (c-kit) and the first-line agent in patients with locally advanced and met
Autor:
Sheima, Farag, Lioe-Fee de, Geus-Oei, Winette T, van der Graaf, Frits, van Coevorden, Dirk, Grunhagen, Anna K L, Reyners, Pieter A, Boonstra, Ingrid, Desar, Hans, Gelderblom, Neeltje, Steeghs
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 59(2)
Autor:
J. Martijn Kerst, Neeltje Steeghs, Annemiek Cats, Alwin D. R. Huitema, Remy B. Verheijen, Sheima Farag
Publikováno v:
Clinical pharmacokinetics. 56(3)
Low trough imatinib concentration (C min) values have been associated with poor clinical outcomes in gastrointestinal stromal tumour (GIST) patients. This study describes the pharmacokinetics of imatinib in a large cohort of GIST patients in routine